NetScientific: refinanced and focused on enhancing value

0
16
  • NetScientific gets shareholder backing for placing
NetScientific PLC -

Quick facts: NetScientific PLC

Follow

View company profile

NetScientific PLC is a holding company, that invests in, develops, commercialises and realises shareholder value in life sciences/healthcare, sustainability and technology companies, which offer significant growth potential predominately in the UK and USA, as well as globally.

With the acquisition of EMV Capital in August 2020, the Group doubled its portfolio from 8 to 17 companies, either through direct subsidiary, balance sheet investment or capital under advisory, varying from start-up private companies to publicly listed equities.

28 Jun 2021

() said shareholders have approved its GBP7.7mlm placing while its portfolio companies have reported significant commercial developments that will drive strong future growth.

Fair value has increased by around 40% on the year-end and now represents a premium to the market value of 38%, noted the investment group’s statement.

John Clarkson, chairman, said: “On behalf of the Board I want to express our gratitude to current and new shareholders for their overwhelming vote of support. This demonstrates confidence in the strategy to deliver further progress and shareholder value. The company is now well-positioned for future success.”

Dr Ilian Iliev, chief executive, added: “We are driving ahead with the execution of the business plans and analyst coverage of the company has now restarted. This combines the use of ‘capital-light investment, pro-active management, value-added support to our portfolio, trans-Atlantic synergies, and new opportunities to realise returns.”

Read more

22 Jun 2021

() said its portfolio company, (), has closed its underwritten public offering of shares.

The shares were offered at US$8.50 a pop. NetScientific participated in the share offering, buying 60,000 shares, which means its stake in PDS is about 4.72%.

Read more

16 Jun 2021

WH Ireland applauded the progress of () investee company (NASDAQ: PDSB), which has unveiled plans to raise US$45mln.

The broker said the latest funding round underlined investor confidence in the prospects for PDS and interest in its immuno-oncology platform, Versamune.

Read more

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…

FOR OUR FULL DISCLAIMER CLICK HERE

TomCo Energy: Moving ahead with new oil-sands technology

Proactive analyst Ed Stacey talks to Katie Pilbeam about TomCo (LON:TOM) an oil & gas exploration and production company which operates in the Uinta Basin in Utah.

In June 2020 the company announced the formation of a joint venture (JV) called Greenfield Energy LLC to unlock the potential…

17 hours, 41 minutes ago

5 min read

LEAVE A REPLY

Please enter your comment!
Please enter your name here